QUADFUTUREBSEQUADRANT FUTURE TEK LTD· Industrial ProductsHighNeutral
Announced Mon, 31 Aug, 2026 · 13:44 IST

Quadrant Future Tek submits Annual Report for FY 2025-26

Pat NegativeEbitda Margin CompressionResults View source PDFExplain this filing

QUADFUTURE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-1.5%Reaction day
₹428.25
prior close
₹421.35
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.3%-1.8% vs market
Cables - Electricals peers, median of 11sector+0.8%-2.2% vs sector

On the reaction day the stock moved 1.8 pts less than Nifty Microcap 250 and 2.2 pts less than its Cables - Electricals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.2
10m
+0.1
15m
+0.1
30m
+0.0
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-1.5+0.3-1.8+0.8-2.2
Next day
-2.3-0.7-1.6-1.3-1.0
2d
-2.7-1.2-1.4-2.8+0.1
3d
-0.7-0.7-0.1-1.9+1.1
4d
-1.7+0.0-1.7-5.9+4.2
5d
-2.9+0.4-3.3-5.5+2.6
1w
+2.1+0.8+1.3-6.0+8.1
15d
+22.2-0.0+22.3-5.3+27.5
1m
+27.7-0.8+28.5-10.6+38.3
2m
—————
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Cables - Electricals peers, median of 11Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Quadrant Future Tek filed its FY 2025-26 Annual Report. Revenue grew 2% YoY to ₹1,530 Mn, with 70% Q4 sequential growth from specialty cables in Railways and Defence. The company reported losses: EBITDA at minus ₹340 Mn and PAT at minus ₹429 Mn, hit by R&D and higher input costs. Order book stands at ₹8,612 Mn, including ₹8,054 Mn in TCAS. KAVACH 4.0 received RDSO approval for passenger trials. AGM set for September 25, 2026.

Likely market impact

Losses continue, but strong ₹8,612 Mn order book and KAVACH 4.0 trial approval signal future growth potential for shareholders.